

iZafe Group AB appoints the Nomination Committee

Stockholm, Sweden - iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) - a leading Life-Science company in healthcare digitalization announces that the company's major shareholders have appointed a nomination committee. iZafe Group AB's major shareholders and group of owners have, in consultation with the Chairman of the Board, Thomas Ahlerup, appointed the following representatives to be part of the Nomination Committee:

- Torgny Ander, appointed by Göran Sjönell
- Sten Röing, own holding
- Peter Werner, appointed by the ownership group Hermansson - Segerström
- Thomas Ahlerup, Chairman of the Board, iZafe Group AB
- Torgny Ander has been appointed Chairman of the Nomination Committee.

The Nomination Committee's task is to present proposals to the Chairman of the Annual General Meeting, the Board, the Chairman of the Board and auditors prior to the 2021 Annual General Meeting, as well as proposals for fees to the Board members as well as remuneration of auditors.

Shareholders in iZafe Group AB are welcome to submit proposals to the Chairman of the Nomination Committee by e-mail valberedning@izafegroup.com or by post to: iZafe Group AB, Nomination Committee, Grev Turegatan 11A, 114 46 Stockholm.

If you have any questions, please contact:

Torgny Ander: valberedning@izafegroup.com

Thomas Ahlerup: thomas.ahlerup@izafegroup.com

Contacts

Thomas Ahlerup, Chairman of the board and Investor Contact

E-mail: thomas.ahlerup@izafegroup.com

Phone number: +46-7868-966 300

iZafe Group AB (publ)

Grev Turegatan 11A

114 46 Stockholm

E-mail: ir@izafegroup.com

www.izafegroup.com/investorrelations

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafegroup.com/investorrelations.

Attachments

[iZafe Group AB appoints the Nomination Committee](#)